Back to top

Video Blog

On Wednesday, November 9th, Mylan (MYL - Free Report) will release its third quarter earnings results after the bell. The company is a Zacks Rank 4 (Sell), and have a Value, Growth, and Momentum score of C.

Dave will look at Mylan’s past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.

Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Mylan ahead of earnings.

Mylan in Focus

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.

Mylan is expected to report earnings at $1.51 a share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 0.87% at $1.16 per share, beating estimates of $1.15 a share.

MYLAN NV Price, Consensus and EPS Surprise

MYLAN NV Price, Consensus and EPS Surprise | MYLAN NV Quote

Mylan is trading around $36 a share, and they are near their 52-week low of $33.60. A major reason for Mylan is trading near their 52-week low is because of recent controversy over their price hike on the EpiPen. Furthermore, Mylan has experienced further controversy with lawmakers questioning their Medicaid rebates for EpiPen. We have a full earnings preview here, and their average EPS surprise is 0.86%.

Bottom Line

How should investors play Mylan ahead of their earnings report? For insights on the best options trades, make sure you are subscribe to Live Trader to see Dave Bartosiak at 1:30 pm this afternoon.

Confidential from Zacks

Would you like to access Zacks' 2 best trades that are not available to the public? Zacks Executive VP, Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered. Today he is prepared to pass the Best of Our Best along to you. See these timely buys now >>


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MYLAN NV (MYL) - free report >>